Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Avelumab + Axitinib & Renal cell carcinoma (RCC), Avelumab + Axitinib is approved by both FDA and EMA as first‑line treatment for advanced/ metastatic Renal cell carcinoma (RCC) (1, 2)
Avelumab + Axitinib demonstrated superior response rates and progression-free survival compared to sunitinib. However, after follow-up of 11.6 months, there was no significant difference in overall survival (OS) (…